AXGN
Axogen, Inc.
Price Chart
Latest Quote
$44.48
+1.08 (+2.49%)
Current Price
| Previous Close | $43.40 |
| Open | $42.46 |
| Day High | $45.68 |
| Day Low | $42.25 |
| Volume | 928,434 |
Stock Information
| Shares Outstanding | 53.18M |
| Total Debt | $20.64M |
| Cash Equivalents | $101.60M |
| Revenue | $238.10M |
| Net Income | $-31.45M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $2.37B |
| EPS (TTM) | $-0.64 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.23B |
| Sales | $238.10M |
| Income | $-31.45M |
| Book/sh | $4.61 |
| Cash/sh | $1.91 |
| Employees | 622 |
Financial Ratios
| Quick Ratio | 4.99 |
| Current Ratio | 7.10 |
| Debt/Eq | 8.43 |
Returns & Margins
| ROA | -2.32% |
| ROE | -17.96% |
| Gross Margin | 75.01% |
| Operating Margin | -4.61% |
| Profit Margin | -13.21% |
Ownership
| Insider Ownership | 2.10% |
| Institutional Ownership | 94.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 61.07 |
| PEG | 99.04 |
| P/S | 9.93 |
| P/B | 9.66 |
Analyst Data
| Recommendation | none |
| Target Price | $50.78 |
Technical Indicators
| SMA20 | $41.64 |
| SMA50 | $40.21 |
| SMA200 | $30.25 |
| RSI | 64.62 |
| ATR | 2.1836 |
| Shares Float | 52.04M |
| Short Float | 7.34% |
| Short Ratio | 3.96 |
| Volatility | 1.12 |
| Rel Volume | 0.86 |
Performance History
| Week | +7.59% |
| Month | +6.03% |
| Quarter | +43.76% |
| 6 Months | +49.36% |
| YTD | +43.48% |
| Year | +356.19% |
| 3 Years | +386.64% |
| 5 Years | +125.90% |
| 10 Years | +653.88% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $44.48 | 928,434 |
| 2026-06-16 | $43.40 | 1,982,500 |
| 2026-06-15 | $43.74 | 2,883,200 |
| 2026-06-12 | $43.00 | 1,553,300 |
| 2026-06-11 | $42.36 | 1,761,900 |
| 2026-06-10 | $41.34 | 1,240,200 |
| 2026-06-09 | $42.87 | 1,138,600 |
| 2026-06-08 | $41.46 | 1,104,700 |
| 2026-06-05 | $42.80 | 817,300 |
| 2026-06-04 | $42.39 | 1,043,700 |
| 2026-06-03 | $40.63 | 574,700 |
| 2026-06-02 | $39.46 | 583,800 |
| 2026-06-01 | $38.72 | 885,600 |
| 2026-05-29 | $39.48 | 840,900 |
| 2026-05-28 | $40.42 | 787,000 |
| 2026-05-27 | $39.87 | 950,900 |
| 2026-05-26 | $41.45 | 699,100 |
| 2026-05-22 | $40.90 | 515,600 |
| 2026-05-21 | $41.31 | 504,000 |
| 2026-05-20 | $42.69 | 904,300 |
| 2026-05-19 | $42.69 | 1,308,100 |
| 2026-05-18 | $41.95 | 898,000 |
About Axogen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
đ° Latest News
Dow Jones AI Giant Nvidia Stock Tumbles To Key Support Level Amid Market Sell-Off
Investor's Business Daily âĸ 2026-06-09T19:35:20Z
Eli Lilly Leads Medical Stocks To Watch, While Google Finds Support
Investor's Business Daily âĸ 2026-06-06T12:00:14Z
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
Investor's Business Daily âĸ 2026-06-05T19:57:02Z
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
MarketBeat âĸ 2026-05-14T15:06:59Z
Axogen, Inc. (NASDAQ:AXGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St. âĸ 2026-04-30T19:25:03Z
Axogen Inc (AXGN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses
GuruFocus.com âĸ 2026-04-29T07:03:23ZSector Update: Health Care Stocks Edge Higher Late Afternoon
MT Newswires âĸ 2026-04-28T19:50:40ZAxogen (AXGN) Q3 2025 Earnings Transcript
Motley Fool âĸ 2026-04-28T19:30:04Z
Axogen (AXGN) Q1 2025 Earnings Transcript
Motley Fool âĸ 2026-04-28T19:29:16Z
AxoGen Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-28T14:17:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $57,855,000 | $45,361,000 | $37,143,000 | $29,775,000 |
| Cost Of Revenue | $57,855,000 | $45,361,000 | $37,143,000 | $29,775,000 |
| Total Revenue | $225,208,000 | $187,338,000 | $159,012,000 | $138,584,000 |
| Operating Revenue | $225,208,000 | $187,338,000 | $159,012,000 | $138,584,000 |
| Expenses | ||||
| Interest Expense | $7,702,000 | $8,206,000 | $2,835,000 | $624,000 |
| Total Expenses | $233,057,000 | $190,625,000 | $180,474,000 | $168,291,000 |
| Other Income Expense | $-152,000 | $1,529,000 | $2,581,000 | $1,383,000 |
| Other Non Operating Income Expenses | $167,000 | $-199,000 | $-437,000 | $-230,000 |
| Net Non Operating Interest Income Expense | $-7,702,000 | $-8,206,000 | $-2,835,000 | $-624,000 |
| Interest Expense Non Operating | $7,702,000 | $8,206,000 | $2,835,000 | $624,000 |
| Operating Expense | $175,202,000 | $145,264,000 | $143,331,000 | $138,516,000 |
| Selling And Marketing Expense | $97,740,000 | $78,461,000 | $77,580,000 | $71,983,000 |
| General And Administrative Expense | $44,577,000 | $39,036,000 | $38,412,000 | $40,906,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Net Interest Income | $-7,702,000 | $-8,206,000 | $-2,835,000 | $-624,000 |
| Normalized Income | $-15,384,000 | $-11,692,000 | $-24,734,000 | $-30,561,000 |
| Net Income From Continuing And Discontinued Operation | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Total Operating Income As Reported | $-7,849,000 | $-3,287,000 | $-21,462,000 | $-29,707,000 |
| Net Income Common Stockholders | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Net Income | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Net Income Including Noncontrolling Interests | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Net Income Continuous Operations | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Pretax Income | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Operating Income | $-7,849,000 | $-3,287,000 | $-21,462,000 | $-29,707,000 |
| Gross Profit | $167,353,000 | $141,977,000 | $121,869,000 | $108,809,000 |
| Per Share | ||||
| Diluted EPS | $-0.34 | $-0.23 | $-0.51 | $-0.69 |
| Basic EPS | $-0.34 | $-0.23 | $-0.51 | $-0.69 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $826,000 | $4,351,000 | $-16,346,000 | $-25,084,000 |
| Total Unusual Items | $-319,000 | $1,728,000 | $3,018,000 | $1,613,000 |
| Total Unusual Items Excluding Goodwill | $-319,000 | $1,728,000 | $3,018,000 | $1,613,000 |
| Reconciled Depreciation | $8,508,000 | $7,837,000 | $5,553,000 | $4,853,000 |
| EBITDA (Bullshit earnings) | $507,000 | $6,079,000 | $-13,328,000 | $-23,471,000 |
| EBIT | $-8,001,000 | $-1,758,000 | $-18,881,000 | $-28,324,000 |
| Diluted Average Shares | $46,050,266 | $44,257,754 | $42,878,543 | $42,083,125 |
| Basic Average Shares | $46,050,266 | $44,257,754 | $42,878,543 | $42,083,125 |
| Diluted NI Availto Com Stockholders | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Gain On Sale Of Security | $-319,000 | $1,728,000 | $3,018,000 | $1,613,000 |
| Research And Development | $32,885,000 | $27,767,000 | $27,339,000 | $25,627,000 |
| Selling General And Administration | $142,317,000 | $117,497,000 | $115,992,000 | $112,889,000 |
| Other Gand A | $44,577,000 | $39,036,000 | $38,412,000 | $40,906,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $122,097,000 | $98,328,000 | $91,134,000 | $97,350,000 |
| Total Assets | $221,687,000 | $203,728,000 | $196,827,000 | $195,387,000 |
| Total Non Current Assets | $101,265,000 | $104,511,000 | $108,823,000 | $97,312,000 |
| Goodwill And Other Intangible Assets | $6,750,000 | $5,579,000 | $4,531,000 | $3,649,000 |
| Other Intangible Assets | $6,750,000 | $5,579,000 | $4,531,000 | $3,649,000 |
| Current Assets | $120,422,000 | $99,217,000 | $88,004,000 | $98,075,000 |
| Other Current Assets | $6,352,000 | $2,447,000 | $2,811,000 | $1,944,000 |
| Restricted Cash | $4,000,000 | $6,000,000 | $6,002,000 | $6,251,000 |
| Inventory | $42,373,000 | $33,183,000 | $23,020,000 | $18,905,000 |
| Receivables | $26,169,000 | $24,105,000 | $25,147,000 | $22,186,000 |
| Accounts Receivable | $26,169,000 | $24,105,000 | $25,147,000 | $22,186,000 |
| Allowance For Doubtful Accounts Receivable | $-948,000 | $-788,000 | $-337,000 | $-650,000 |
| Gross Accounts Receivable | $27,117,000 | $24,893,000 | $25,484,000 | $22,836,000 |
| Cash Cash Equivalents And Short Term Investments | $41,528,000 | $33,482,000 | $31,024,000 | $48,789,000 |
| Cash And Cash Equivalents | $35,548,000 | $27,554,000 | $31,024,000 | $15,284,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $12,839,000 | $19,942,000 | $15,579,000 | $30,428,000 |
| Total Debt | $67,629,000 | $68,686,000 | $69,292,000 | $67,427,000 |
| Long Term Debt And Capital Lease Obligation | $65,257,000 | $66,717,000 | $67,745,000 | $66,117,000 |
| Long Term Debt | $48,387,000 | $47,496,000 | $46,603,000 | $45,712,000 |
| Current Debt And Capital Lease Obligation | $2,372,000 | $1,969,000 | $1,547,000 | $1,310,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $92,840,000 | $99,821,000 | $101,162,000 | $94,388,000 |
| Total Non Current Liabilities Net Minority Interest | $69,284,000 | $69,211,000 | $70,732,000 | $70,635,000 |
| Other Non Current Liabilities | $141,000 | $94,000 | - | - |
| Derivative Product Liabilities | $3,886,000 | $2,400,000 | $2,987,000 | $4,518,000 |
| Current Liabilities | $23,556,000 | $30,610,000 | $30,430,000 | $23,753,000 |
| Payables And Accrued Expenses | $4,559,000 | $10,058,000 | $14,954,000 | $13,484,000 |
| Payables | $2,888,000 | $8,008,000 | $11,774,000 | $8,964,000 |
| Accounts Payable | $2,888,000 | $8,008,000 | $11,774,000 | $8,964,000 |
| Equity | ||||
| Common Stock Equity | $128,847,000 | $103,907,000 | $95,665,000 | $100,999,000 |
| Total Equity Gross Minority Interest | $128,847,000 | $103,907,000 | $95,665,000 | $100,999,000 |
| Stockholders Equity | $128,847,000 | $103,907,000 | $95,665,000 | $100,999,000 |
| Retained Earnings | $-306,963,000 | $-291,260,000 | $-281,296,000 | $-259,580,000 |
| Other | ||||
| Ordinary Shares Number | $47,199,797 | $44,148,836 | $43,124,496 | $42,445,517 |
| Share Issued | $47,199,797 | $44,148,836 | $43,124,496 | $42,445,517 |
| Tangible Book Value | $122,097,000 | $98,328,000 | $91,134,000 | $97,350,000 |
| Invested Capital | $177,234,000 | $151,403,000 | $142,268,000 | $146,711,000 |
| Working Capital | $96,866,000 | $68,607,000 | $57,574,000 | $74,322,000 |
| Capital Lease Obligations | $19,242,000 | $21,190,000 | $22,689,000 | $21,715,000 |
| Total Capitalization | $177,234,000 | $151,403,000 | $142,268,000 | $146,711,000 |
| Additional Paid In Capital | $435,338,000 | $394,726,000 | $376,530,000 | $360,155,000 |
| Capital Stock | $472,000 | $441,000 | $431,000 | $424,000 |
| Common Stock | $472,000 | $441,000 | $431,000 | $424,000 |
| Long Term Capital Lease Obligation | $16,870,000 | $19,221,000 | $21,142,000 | $20,405,000 |
| Current Capital Lease Obligation | $2,372,000 | $1,969,000 | $1,547,000 | $1,310,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $16,625,000 | $18,583,000 | $13,929,000 | $8,959,000 |
| Current Accrued Expenses | $1,671,000 | $2,050,000 | $3,180,000 | $4,520,000 |
| Net PPE | $94,515,000 | $98,932,000 | $104,292,000 | $93,663,000 |
| Accumulated Depreciation | $-26,430,000 | $-19,911,000 | $-13,697,000 | $-10,296,000 |
| Gross PPE | $120,945,000 | $118,843,000 | $117,989,000 | $103,959,000 |
| Leases | $18,060,000 | $17,977,000 | $15,348,000 | $15,482,000 |
| Construction In Progress | $1,241,000 | $1,499,000 | $3,674,000 | $63,703,000 |
| Other Properties | $29,384,000 | $28,374,000 | $28,816,000 | $18,727,000 |
| Machinery Furniture Equipment | $10,850,000 | $9,583,000 | $8,741,000 | $5,316,000 |
| Buildings And Improvements | $60,679,000 | $60,679,000 | $60,679,000 | $0 |
| Land And Improvements | $731,000 | $731,000 | $731,000 | $731,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $35,975,000 | $27,054,000 | $13,545,000 | $12,651,000 |
| Work In Process | $1,215,000 | $1,325,000 | $2,120,000 | $1,026,000 |
| Raw Materials | $5,183,000 | $4,804,000 | $7,355,000 | $5,228,000 |
| Other Short Term Investments | $5,980,000 | $5,928,000 | $0 | $33,505,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,782,000 | $11,000 | $-20,634,000 | $-37,319,000 |
| Operating Activities | ||||
| Operating Cash Flow | $812,000 | $4,535,000 | $-5,716,000 | $-16,066,000 |
| Cash Flow From Continuing Operating Activities | $812,000 | $4,535,000 | $-5,716,000 | $-16,066,000 |
| Operating Gains Losses | $1,158,000 | $-742,000 | $-2,141,000 | $-1,272,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,594,000 | $-4,524,000 | $-14,918,000 | $-21,253,000 |
| Investing Cash Flow | $-5,317,000 | $-10,297,000 | $19,253,000 | $-3,200,000 |
| Cash Flow From Continuing Investing Activities | $-5,317,000 | $-10,297,000 | $19,253,000 | $-3,200,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $10,499,000 | $2,290,000 | $1,954,000 | $1,794,000 |
| Cash Flow From Continuing Financing Activities | $10,499,000 | $2,290,000 | $1,954,000 | $1,794,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-32,000 | $-10,000 | $-10,000 | $-12,000 |
| Interest Paid Supplemental Data | $6,811,000 | $7,301,000 | $1,944,000 | $0 |
| End Cash Position | $39,548,000 | $33,554,000 | $37,026,000 | $21,535,000 |
| Beginning Cash Position | $33,554,000 | $37,026,000 | $21,535,000 | $39,007,000 |
| Changes In Cash | $5,994,000 | $-3,472,000 | $15,491,000 | $-17,472,000 |
| Proceeds From Stock Option Exercised | $10,531,000 | $2,300,000 | $1,964,000 | $1,806,000 |
| Net Issuance Payments Of Debt | $-32,000 | $-10,000 | $-10,000 | $-12,000 |
| Net Long Term Debt Issuance | $-32,000 | $-10,000 | $-10,000 | $-12,000 |
| Long Term Debt Payments | $-32,000 | $-10,000 | $-10,000 | $-12,000 |
| Net Investment Purchase And Sale | $277,000 | $-5,773,000 | $34,171,000 | $18,053,000 |
| Sale Of Investment | $14,000,000 | $0 | $44,374,000 | $57,300,000 |
| Purchase Of Investment | $-13,723,000 | $-5,773,000 | $-10,203,000 | $-39,247,000 |
| Net Intangibles Purchase And Sale | $-1,849,000 | $-1,423,000 | $-1,046,000 | $-1,175,000 |
| Purchase Of Intangibles | $-1,849,000 | $-1,423,000 | $-1,046,000 | $-1,175,000 |
| Net PPE Purchase And Sale | $-3,745,000 | $-3,101,000 | $-13,872,000 | $-20,078,000 |
| Purchase Of PPE | $-3,745,000 | $-3,101,000 | $-13,872,000 | $-20,078,000 |
| Interest Paid Cfo | $-11,000 | $-4,000 | $-3,000 | $-2,000 |
| Change In Working Capital | $-24,607,000 | $-10,041,000 | $-2,447,000 | $-7,791,000 |
| Change In Other Current Liabilities | $-1,890,000 | $-1,179,000 | $-1,283,000 | $-1,841,000 |
| Change In Payables And Accrued Expense | $-7,158,000 | $125,000 | $6,509,000 | $660,000 |
| Change In Prepaid Assets | $-3,905,000 | $784,000 | $-867,000 | $-84,000 |
| Change In Inventory | $-9,190,000 | $-10,163,000 | $-4,115,000 | $-1,887,000 |
| Change In Receivables | $-2,464,000 | $392,000 | $-2,691,000 | $-4,639,000 |
| Changes In Account Receivables | $-2,464,000 | $392,000 | $-2,691,000 | $-4,639,000 |
| Other Non Cash Items | $891,000 | $893,000 | $891,000 | $891,000 |
| Stock Based Compensation | $30,112,000 | $15,906,000 | $14,418,000 | $15,591,000 |
| Provisionand Write Offof Assets | $400,000 | $650,000 | $-271,000 | $612,000 |
| Asset Impairment Charge | $64,000 | $0 | $0 | $1,769,000 |
| Depreciation Amortization Depletion | $8,508,000 | $7,837,000 | $5,553,000 | $4,853,000 |
| Depreciation And Amortization | $8,508,000 | $7,837,000 | $5,553,000 | $4,853,000 |
| Amortization Cash Flow | $315,000 | $267,000 | $273,000 | $265,000 |
| Amortization Of Intangibles | $315,000 | $267,000 | $273,000 | $265,000 |
| Depreciation | $8,193,000 | $7,570,000 | $5,280,000 | $4,588,000 |
| Gain Loss On Investment Securities | $1,158,000 | $-742,000 | $-2,197,000 | $-1,272,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $56,000 | $0 |
| Net Income From Continuing Operations | $-15,703,000 | $-9,964,000 | $-21,716,000 | $-28,948,000 |
| Change In Other Working Capital | - | $424,000 | $-14,000 | - |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-14